Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
  • Publication number: 20240226443
    Abstract: Provided is a syringe including: a barrel; and a partitioning device, the partitioning device including: a cylindrical housing; and an inner plug, the housing including an engaging part configured to engage with the inner plug in an out-of-communication state, the inner plug including an engaged part configured to engage with the engaging part from a proximal side in the out-of-communication state, and the partitioning device being configured so that, when a pressing force is applied from the proximal side, one of the engaging part and the engaged part rides over an other one thereof and release engagement between the engaging part and the engaged part, thereby allowing the inner plug to have the proximal side space inside the housing and the distal side space inside the housing communicating with each other to achieve communication between the proximal side space inside the barrel and the distal side space inside the barrel.
    Type: Application
    Filed: May 2, 2022
    Publication date: July 11, 2024
    Applicants: TAISEI KAKO CO., LTD., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Yuji YAMANAKA, Kiichi EGAMI, Ayano HORIKAWA, Taiji HORITA, Yukihiro OGAWA, Kensuke TANIGUCHI, Junki MIYAGAWA
  • Patent number: 12030955
    Abstract: The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 9, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa, Tatsuya Kawa
  • Publication number: 20240190976
    Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
    Type: Application
    Filed: January 29, 2024
    Publication date: June 13, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
  • Patent number: 12005064
    Abstract: The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: June 11, 2024
    Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Susanne Meier, Carsten Bruesewitz
  • Publication number: 20240183826
    Abstract: The present disclosure provides an analysis method for measuring the content of light chain-exchanged molecules in a composition containing a multi-specific antigen-binding molecule. The analysis method of the present disclosure includes the steps of: treating a composition comprising a multi-specific antigen-binding molecule and preparing a plurality of types of F(ab) fragments; and measuring the F(ab) fragments by a separation method based on electric charge or hydrophobic interactions and determining the content (content ratio) of each fragment.
    Type: Application
    Filed: April 1, 2021
    Publication date: June 6, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Motohiko Sato, Hiroko Murata
  • Publication number: 20240158520
    Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 16, 2024
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao
  • Publication number: 20240158785
    Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 16, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
  • Publication number: 20240158482
    Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.
    Type: Application
    Filed: December 20, 2023
    Publication date: May 16, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
  • Publication number: 20240150477
    Abstract: The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takahiro Kakehi, Akinori Yamada, Yoshimasa Ishida
  • Publication number: 20240139192
    Abstract: The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 8, 2023
    Publication date: May 2, 2024
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jan ECKMANN, Thomas FRIESS, Frank HERTING, Yusuke IDE, Hiroshi TANAKA, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
  • Patent number: 11965180
    Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: April 23, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
  • Patent number: 11964950
    Abstract: The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X1, X2, X3 and X4 are each independently —CR2? or N?, R2 is, for example, a halogen atom, R1 is, for example, —S(?O)2—NH—R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 23, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshiaki Isshiki, Fumio Watanabe, Masaki Tomizawa, Kihito Hada, Kazuo Hattori, Kenichi Kawasaki, Ikumi Hyodo, Toshihiro Aoki
  • Publication number: 20240117059
    Abstract: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug a
    Type: Application
    Filed: December 8, 2023
    Publication date: April 11, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Futa Mimoto, Taichi Kuramochi
  • Publication number: 20240115578
    Abstract: ALK abnormalities are widely found in a variety of pediatric malignant solid tumors, and ALK inhibitors against ALK abnormalities are considered an important target in the development of treatment in the field of pediatric oncology. According to the present invention, it is possible to provide a pharmaceutical composition for the treatment of childhood cancer with an ALK abnormality, with a novel dosage and administration, comprising alectinib or a salt thereof, and to be used in the treatment of cancer in children under the age of 2.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 11, 2024
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Jotaro SATO, Chie EMOTO, Mikiko NAKAMURA
  • Patent number: 11952422
    Abstract: Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: April 9, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Shun Shimizu, Shu Wen Samantha Ho, Naoka Hironiwa, Mika Sakurai, Taro Miyazaki, Tomoyuki Igawa
  • Publication number: 20240100058
    Abstract: The present invention provides a method for determining a sodium lauryl sulfate having a desired quality as a pharmaceutical raw material for a formulation by detecting a slight difference in quality of sodium lauryl sulfate to be used as a pharmaceutical raw material for a formulation. The present invention relates to a method for sorting a raw material for a formulation which can provide a pharmaceutical formulation excellent in stability by pretreating the material for a formulation under a predetermined accelerated condition and detecting an impurity. According to the method of the present invention, it is possible to determine the quality of sodium lauryl sulfate of a pharmaceutical raw material for a formulation having no effect on the quality of a pharmaceutical formulation containing alectinib or a salt thereof.
    Type: Application
    Filed: December 25, 2020
    Publication date: March 28, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tadanobu NAKAYAMA, Yoshiko KURE, Takuro SASAYAMA
  • Patent number: 11939322
    Abstract: This invention relates to a method for manufacturing 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, and is industrially preferable, allowing an objective substance to be obtained in high yield more safely and easily than the conventional method.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 26, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroki Serizawa, Akira Kawase, Hiroshi Fukuda, Naoto Hama
  • Patent number: 11932435
    Abstract: The present invention provides a filling nozzle obtained by using a resin selected from a cycloolefin polymer and a cycloolefin copolymer, or a filling nozzle including a tubular passage for supplying a pharmaceutical solution, and a filling port disposed at a lower end of the tubular passage, in which the tubular passage and the filling port have a circular peripheral cross-section, and an inner diameter of the passage of the filling port is larger than an inner diameter of the tubular passage disposed on an upstream side.
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: March 19, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Shaw Nishizawa
  • Patent number: 11932697
    Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: March 19, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa
  • Publication number: 20240083939
    Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 14, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito